Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease
Authors:
- Kazushi SuzukiKSKazushi Suzuki
- Atsushi IwataAIAtsushi Iwata
- Takeshi IwatsuboTITakeshi Iwatsubo
- Japanese Alzheimer'S Disease Neuroimaging Initiative Alzheimer'S Disease Neuroimaging InitiativeJIJapanese Alzheimer'S Disease Neuroimaging Initiative Alzheimer'S Disease Neuroimaging Initiative
Open Access
- 1 January 2020
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 6 (1) , e12007
Abstract
Introduction: Possession of the apolipoprotein E ( APO E ) ε4 allele advances amyloid β (Aβ) deposition and symptomatic onset of Alzheimer's disease (AD), whereas its effect on the rate of cognitive decline remained controversial. We examined the effects of APOE ε4 allele on cognition in biomarker‐confirmed late mild cognitive impairment (LMCI) and mild AD subjects in the Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and North American ADNI (NA‐ADNI). Methods: The “early AD” (ie, combined LMCI and mild AD) cohort of 649 subjects from J‐ADNI and NA‐ADNI were selected based on positivity of Aβ confirmed by amyloid positron emission tomography (PET) or cerebrospinal fluid testing. The rates of cognitive decline in the Mini Mental State Examination (MMSE), the Clinical Dementia Rating Sum of Boxes (CDR‐SB), and the Alzheimer's Disease Assessment Scale‐cognitive subscale 13 (ADAS‐Cog) from baseline were examined using mixed‐effects model. The effect of ε4 on time to conversion to dementia was also analyzed in LMCI using the Kaplan‐Meier estimator and log‐rank test. Results: The rates of cognitive decline were not significantly different between ε4 carriers and ε4 non‐carriers in the total early AD cohort, which were affected neither by region nor by the number of ε4 alleles. In LMCI, ε4 carriers showed almost the same progression rates as ε4 non‐carriers, except for a significantly faster decline in MMSE ( P = .0282). Time to conversion to demenita was not significantly different between ε4 carriers and ε4 non‐carriers. In ε4‐positive mild AD, the rates of decline in MMSE ( P = .003) and CDR‐SB ( P = .0071) were slower than those in ε4 non‐carriers. DISCUSSION: The APOE ε4 allele had little effect on the rates of cognitive decline in the overall biomarker‐confirmed early AD, regardless of region and number of ε4 alleles, with a slight variability in different clinical stages, the ε4 allele being slightly accelerative in LMCI, while decelerative in mild AD.Keywords
Funding Information
- Alzheimer's Disease Neuroimaging Initiative
- National Institutes of Health (U01 AG024904)
- U.S. Department of War (W81XWH‐12‐2‐0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Japan Society for the Promotion of Science (17K09794)
- Japan Agency for Medical Research and Development (JP17DK0207028, JP19DK0207048)
This publication has 44 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Apolipoprotein E in Alzheimer's disease and other neurological disordersThe Lancet Neurology, 2011
- Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- The APOE ε4 Allele Is Associated with Incident Mild Cognitive Impairment among Community-Dwelling Older PersonsNeuroepidemiology, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's diseaseThe Pharmacogenomics Journal, 2006
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's diseaseAnnals of Neurology, 1995
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993